Gynecologic Cancer
Guidelines
ASCO advises against PARP inhibitor retreatment in ovarian cancer
ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.
From the Journals
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
Conference Coverage
Lower BP and better tumor control with drug combo?
Feature
Are oncologists ready to confront a second wave of COVID-19?
From the Journals
Two-stage surgery to reduce ovarian cancer risk piques interest
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
Conference Coverage
Atezolizumab strikes out in ovarian cancer
Atezolizumab did not extend progression-free survival.
From the Journals
HPV vaccine shown to substantially reduce cervical cancer risk
A review of more than 1 million girls/women vaccinated in 2006-2017 shows a substantial reduction in the risk for invasive cervical cancer.
Clinical Insights
The scope of under- and overtreatment in older adults with cancer
From the Journals
Cancer disparities: One of the most pressing public health issues
“The burden of cancer is not shouldered equally by all segments of the U.S. population,” the AACR states.
Conference Coverage
Palbociclib plus letrozole improves PFS in advanced endometrial cancer